Keytruda Improves Survival in Triple-Negative Breast Cancer
September 15, 2024
People diagnosed with early-stage triple-negative breast cancer who received the immunotherapy Keytruda (chemical name: pembrolizumab) along with chemotherapy before and after surgery had better event-free survival — how long they lived without the cancer coming back. Read more…